Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial( )

BACKGROUND: Switching to dolutegravir/lamivudine (DTG/3TC) was noninferior to continuing tenofovir alafenamide (TAF)–based regimens for maintaining virologic suppression at week 48 of the TANGO study. Here we present week 144 outcomes (efficacy, safety, weight, and biomarkers). METHODS: TANGO is a r...

Descripción completa

Detalles Bibliográficos
Autores principales: Osiyemi, Olayemi, De Wit, Stéphane, Ajana, Faïza, Bisshop, Fiona, Portilla, Joaquín, Routy, Jean Pierre, Wyen, Christoph, Ait-Khaled, Mounir, Leone, Peter, Pappa, Keith A, Wang, Ruolan, Wright, Jonathan, George, Nisha, Wynne, Brian, Aboud, Michael, van Wyk, Jean, Smith, Kimberly Y
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639798/
https://www.ncbi.nlm.nih.gov/pubmed/35079789
http://dx.doi.org/10.1093/cid/ciac036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639798/
https://www.ncbi.nlm.nih.gov/pubmed/35079789
http://dx.doi.org/10.1093/cid/ciac036

Ejemplares similares